RSV-NET data showed that RSV hospitalization rates among infants aged 0 to 7 months were an estimated 43% (95% confidence ...

The data suggest that the most severe RSV disease among infants up to seven months old is preventable, the CDC said, adding that it is important to protect infants, ideally within ...

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

After the monoclonal antibody nirsevimab (Beyfortus) became available to prevent respiratory syncytial virus (RSV) in infants ...

below 2.0x in 2025-26 with EBITDA and cash flows supported by mid-single-digit sales growth and margin improvements from Dupixent and recent products launches like Beyfortus and Altuviiio. While ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

below 2.0x in 2025-26 with EBITDA and cash flows supported by mid-single-digit sales growth and margin improvements from Dupixent and recent products launches like Beyfortus and Altuviiio.

As sure as the sun rises, prescription medicine use and total drug spending continue to increase in the U.S. | Last year's $50 billion increase in net drug spending marked a period of "historic growth ...

Beyfortus, which has been approved for use in the European Union, US, China, Japan, among several countries globally, received its marketing authorisation approval from India’s Central Drugs ...

Dr Reddy’s Laboratories expands its strategic partnership with Sanofi Healthcare India to introduce a novel drug, Beyfortus (nirsevimab), in India. Beyfortus contains the monoclonal antibody, ...